BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15781380)

  • 1. [Sodium/iodide symporter: physiopathological aspects and therapeutic perspectives].
    Plantin-Carrenard E; Foglietti MJ; Beaudeux JL
    Pathol Biol (Paris); 2005 Apr; 53(3):174-82. PubMed ID: 15781380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells.
    Lundh C; Lindencrona U; Postgård P; Carlsson T; Nilsson M; Forssell-Aronsson E
    J Nucl Med; 2009 Jul; 50(7):1161-7. PubMed ID: 19525464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].
    Spitzweg C
    Internist (Berl); 2003 Apr; 44(4):396-402, 404-8, 410-1. PubMed ID: 12914397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the molecular characterization of the sodium-iodide symporter (NIS).
    Schmutzler C; Köhrle J
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 3():S1-10. PubMed ID: 9865544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound.
    Meller J; Becker W
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S425-38. PubMed ID: 12192542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A perspective view of sodium iodide symporter research and its clinical implications.
    Riesco-Eizaguirre G; Santisteban P
    Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo.
    Zuckier LS; Dohan O; Li Y; Chang CJ; Carrasco N; Dadachova E
    J Nucl Med; 2004 Mar; 45(3):500-7. PubMed ID: 15001694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
    Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The practical relevance of the sodium iodide symporter].
    Spitzweg C
    Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():25-32. PubMed ID: 15255310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minireview: The sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid.
    Bizhanova A; Kopp P
    Endocrinology; 2009 Mar; 150(3):1084-90. PubMed ID: 19196800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium iodide symporter: its role in nuclear medicine.
    Chung JK
    J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium iodide symporter in health and disease.
    Shen DH; Kloos RT; Mazzaferri EL; Jhian SM
    Thyroid; 2001 May; 11(5):415-25. PubMed ID: 11396700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular radiotheragnostics in thyroid disease.
    Singh N; Lewington V
    Clin Med (Lond); 2017 Oct; 17(5):453-457. PubMed ID: 28974598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
    Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
    J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of human sodium/iodide symporter, thyroid transcription factor-1, and paired-box-protein-8 gene expression in benign thyroid diseases.
    Joba W; Spitzweg C; Schriever K; Heufelder AE
    Thyroid; 1999 May; 9(5):455-66. PubMed ID: 10365677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sodium iodide symporter: its pathophysiological and therapeutic implications.
    Spitzweg C; Morris JC
    Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium iodide symporter and pendrin expression in human thyroid tissues.
    Mian C; Lacroix L; Alzieu L; Nocera M; Talbot M; Bidart JM; Schlumberger M; Caillou B
    Thyroid; 2001 Sep; 11(9):825-30. PubMed ID: 11575851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
    Schmutzler C; Winzer R; Meissner-Weigl J; Köhrle J
    Biochem Biophys Res Commun; 1997 Nov; 240(3):832-8. PubMed ID: 9398654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond.
    Dohán O; Carrasco N
    Mol Cell Endocrinol; 2003 Dec; 213(1):59-70. PubMed ID: 15062574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The sodium-iodide-symporter (NIS): function, regulation and clinical importance].
    Köhrle J
    Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():17-22. PubMed ID: 10355044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.